Skip to main content
Figure 1 | BMC Clinical Pharmacology

Figure 1

From: Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy

Figure 1

Sulphobutylether beta cyclodextrin sodium (SBECD) levels in patients on intermittent dialysis receiving intravenous voriconazole. Patients no. 2–4 with acute renal failure without recovery of renal function under intermittent dialysis receiving intravenous voriconazole show higher levels of sulphobutylether beta cyclodextrin sodium (SBECD) as compared to patient no. 1 with recovery of renal function. For comparison, in healthy volunteers peak SBECD levels of 130 μg/ml (dotted line) were measured immediately following administration of 1600 mg SBECD as a single infusion [9].

Back to article page

BMC Clinical Pharmacology

ISSN: 1472-6904